Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Common Equity (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Common Equity for 13 consecutive years, with $602.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 20.11% to $602.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $602.7 million through Dec 2025, down 20.11% year-over-year, with the annual reading at $602.7 million for FY2025, 20.11% down from the prior year.
  • Common Equity for Q4 2025 was $602.7 million at Madrigal Pharmaceuticals, down from $625.7 million in the prior quarter.
  • The five-year high for Common Equity was $857.1 million in Q2 2024, with the low at $10.7 million in Q3 2022.
  • Average Common Equity over 5 years is $397.8 million, with a median of $265.6 million recorded in 2021.
  • The sharpest move saw Common Equity plummeted 95.46% in 2022, then soared 3392.99% in 2024.
  • Over 5 years, Common Equity stood at $196.1 million in 2021, then rose by 0.65% to $197.4 million in 2022, then soared by 105.35% to $405.3 million in 2023, then soared by 86.11% to $754.4 million in 2024, then decreased by 20.11% to $602.7 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $602.7 million, $625.7 million, and $696.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.